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Purpose: This study was designed to determine the rate of ductal carcinoma in situ (DCIS) 
underestimation diagnosed after an ultrasound-guided 14-gauge core needle biopsy (US-14G-
CNB) of breast masses and to compare the clinical and imaging characteristics between true 
DCIS and underestimated DCIS identified following surgical excision.
Methods: Among 3,124 US-14G-CNBs performed for breast masses, 69 lesions in 60 patients 
were pathologically-determined to be pure DCIS. We classified these patients according to the 
final pathology after surgical excision as those with invasive ductal carcinoma (underestimated 
group) and those with DCIS (non-underestimated group). We retrospectively reviewed and 
compared the clinical and imaging characteristics between the two groups.
Results: Of the 69 lesions, 21 were shown after surgery to be invasive carcinomas; the rate 
of DCIS underestimation was 30.4%. There were no statistically significant differences with 
respect to the clinical symptoms, age, lesion size, mammographic findings, and ultrasonographic 
findings except for the presence of abnormal axillary lymph nodes as detected on ultrasound. 
The lesions in 2 patients in the non-underestimated group (2/41, 4.9%) and 5 patients in the 
underestimated group (5/19, 26.3%) were associated with abnormal lymph nodes on axillary 
ultrasound, and the presence of abnormal axillary lymph nodes on ultrasound was statistically 
significant (P=0.016).
Conclusion: We found a 30.4% rate of DCIS underestimation in breast masses based on a US-
14G-CNB. The presence of abnormal lymph nodes as detected on axillary ultrasound may be 
useful to preoperatively predict underestimation.
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Introduction
Ultrasound-guided core needle biopsy (US-CNB) is an invaluable 
tool for the diagnosis of breast lesions and has many advantages 
compared to stereotactic biopsies, including a lack of ionizing 
radiation exposure, increased patient comfort, lower cost, reduced 
procedure time, and real-time visualization of needle placement 
[1-3]. However, the possibility of histologic underestimation of 
lesions and false negative results by core needle biopsy has been 
unavoidable despite improvements in biopsy devices and efforts 
to reduce missed breast cancers, including imaging-pathologic 
correlation with repeat biopsy. Ductal carcinoma in situ (DCIS) 
underestimation occurs when a lesion is determined to be DCIS 
after a percutaneous breast biopsy and is subsequently shown 
to be an invasive carcinoma following surgical excision. The rate 
of underestimation is likely due to sampling error in lesions that 
contain both DCIS and invasive cancer. On mammography, DCIS 
is typically depicted as calcifications, although a lesion may also 
appear as a non-calcified mass. In a review of the literature, most 
prior studies of DCIS underestimation have been performed using 
stereotactic devices, including cases with directional vacuum-
assisted biopsy and those with automated large core needle biopsy, 
and have reported variable underestimation rates ranging from 
5%-44% [4-8]. However, DCIS underestimation after a US-CNB of 
a breast mass has not been thoroughly evaluated, and studies on 
the ultrasonographic factors related to DCIS underestimation after 
a US-CNB are also very rare [9]. The purpose of this study was to 
determine the rate of DCIS underestimation following US-guided 
14-gauge CNB (US-14G-CNB) of a breast mass and to compare the 
clinical and imaging characteristics between true DCIS lesions and 
underestimated DCIS lesions identified following surgical excision.
Materials and Methods
Our Institutional Review Board approved this study. Informed 
consent was not required from patients for this retrospective 
analysis.
Case Selection
Between July 2005 and July 2007, 3,124 US-14G-CNBs of breast 
masses were performed at the breast imaging center at our 
institution. Among the lesions, 78 lesions (2.5%) were pathologically-
determined to be DCIS. The inclusion criterion for this study was a 
histopathologically-proven pure DCIS without signs of microinvasion 
or invasive cancer from a core biopsy specimen as determined by 
the use of light microscopy. DCIS with microinvasion was defined as 
tumor cells, singly or in clusters, that had infiltrated the periductal 
stroma or were seen as a projection of neoplastic cells through 
a disrupted basement membrane in continuity with the DCIS, 
measuring ≤1 mm along the greatest dimension [10]. Excluding 
lesions with microinvasions (n=9), 69 pure DCIS lesions from 60 
patients were identified that manifested as identifiable masses with 
or without calcifications as depicted on ultrasonography and were 
included in the study population. Six patients had two separate 
lesions and one patient had four separate lesions.
Image and Clinical Analysis
All of the patients underwent a clinical breast examination, 
mammography, and breast ultrasonography. The mammograms 
were performed using a Lorad/Hologic Selenia Full Field Digital 
Mammography system (Lorad/Hologic, Danbury, CT, USA). Standard 
craniocaudal and mediolateral oblique views were routinely 
obtained, and additional mammographic views were used as 
needed. Breast ultrasonography was performed by one of five 
radiologists with a specialty in breast imaging, and high-resolution 
ultrasonography units with a 7-12 MHz linear array transducer (ATL 
HDI 5000 or 3000; iU22; Philips Medical System, Bothell, WA, USA) 
were used for breast ultrasonography. 
Two radiologists retrospectively reviewed the mammographic 
and ultrasonographic findings of the biopsied lesions resulting in 
DCIS by consensus. The mammographic characteristics of the lesions 
were classified as negative, calcifications only, a mass, a mass 
with calcifications, asymmetry, and asymmetry with calcifications. 
The ultrasonographic characteristics of size, shape, orientation, 
margin, lesion boundary, and echogenicity of nodules according to 
the American College of Radiology Breast Imaging Reporting and 
Data System (BI-RADS) lexicon were reviewed retrospectively [11]. 
The lesion size was measured according to the maximum lesion 
diameter as measured on ultrasonography. When performing breast 
ultrasonography, the bilateral axillary regions were also assessed 
for the presence of abnormal lymph nodes. An abnormal lymph 
node was defined as a lymph node with an eccentric or irregular 
cortical thickening (usually >3 mm) irrespective of lymph node size, 
round shape (short-to-long diameter ratio >0.5), change in internal 
echogenicity (hyperechoic, cystic change, or calcification), or absent 
or compressed echogenic hilum in accordance with previous reports 
[12-14]. In the ultrasonography evaluation of the axillary lymph 
nodes as normal or abnormal, we did not use a size as a definite 
diagnostic criterion for this study. Although larger nodes tend to 
have a higher incidence of malignancy, reactive nodes can be as 
large as metastatic nodes. Thus, nodal size alone cannot be used to 
distinguish reactive nodes from metastatic lymph nodes. 
The clinical records for the 60 patients were reviewed to 
determine their age and symptoms at the time of presentation. 
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Biopsy Procedure
A US-14G-CNB was performed using a free hand technique and a 
high-resolution ultrasonography unit with a 7-12 MHz linear array 
transducer (ATL HDI 5000 or 3000; iU22). All procedures were 
performed using an automated gun (Pro-Mag 2.2; Manan Medical 
Products, Northbrook, IL, USA) and 14-gauge Tru-Cut needles with 
a 22 mm throw (SACN Biopsy Needle; Medical Device Technologies, 
Gainesville, FL, USA). One of five radiologists specializing in breast 
imaging performed all of the biopsies. Prior to biopsy, a breast 
ultrasonography (including the bilateral axillae) was meticulously 
performed. A minimum of five biopsy samples were obtained with 
additional samples collected at the discretion of the radiologist. 
Informed consent was obtained from each patient undergoing a 
biopsy. The pathologic results of the US-14G-CNBs for each case 
were retrospectively reviewed with the final pathology findings as 
determined after breast surgery. 
Data Analysis
The results of the US-14G-CNBs were correlated with the subsequent 
surgical (conserving surgery or mastectomy) histologic findings. 
Axillary lymph node status was determined after a sentinel 
lymph node biopsy or axillary lymph node dissection. The rate of 
underestimation was defined as a diagnosis of DCIS after a US-14G-
CNB with a pathologic diagnosis of invasive carcinoma following 
surgery. The patients were classified into either the underestimated 
or non-underestimated group. The underestimated group was 
defined as cases diagnosed as DCIS after a US-14G-CNB but 
later determined to be invasive ductal carcinoma (IDC) following 
surgical excision. The non-underestimated group consisted of cases 
diagnosed as DCIS after a US-14G-CNB and determined not to 
have invasive cancer following surgical excision. We evaluated the 
differences between the underestimated and non-underestimated 
groups in terms of age, clinical symptoms, mammographic findings 
and ultrasonographic characteristics, including axillary findings. 
Tests for statistical significance were performed using SPSS ver. 12.0 
(SPSS Inc., Chicago, IL, USA). A P<0.05 was considered significant. 
Statistical comparisons were performed using the chi-squared test 
(Fisher exact test) for categorical variables and the independent 
t-test for continuous variables. Confidence intervals were calculated 
according to the formula developed by Berry [15].
Results
All 60 patients were women (age range, 24 to 88 years; mean age, 
47.5±11.3 years). Of the 69 lesions diagnosed as DCIS after US-
14G-CNB, invasive carcinoma was diagnosed following surgical 
excision in 21 lesions from 19 patients (the underestimated 
group). Thus, the DCIS underestimation rate in this study was 
30.4% (95% confidence interval, 17.4 to 38.0). The lesion size 
of the underestimated group was larger than that of the non-
underestimated group (2.3 cm vs. 1.6 cm on ultrasonography; 
2.7 cm vs. 2.1 cm on mammography); however, no significant 
difference was found in size between the underestimated and non-
underestimated groups. Comparisons of the underestimated and 
non-underestimated groups are summarized in Tables 1-3. 
No differences were found between the underestimated and 
non-underestimated groups in terms of age, clinical symptoms, 
and mammographic findings. In the analysis of ultrasonographic 
findings, the rate of presence of abnormal lymph node depicted 
on ultrasonography in underestimated group was higher than that 
in the non-underestimated group (26.3% [5/19 lesions] vs. 4.9% 
[2/14 lesions], P=0.016, respectively) (Figs. 1, 2). No statistically 
significant differences were identified between the underestimated 
Table 1. Comparisons of clinical findings in the 21 
underestimated and 48 non-underestimated DCIS lesions
Clinical finding 
Underestimated 
(n=21)
Non-
underestimated 
(n=48)
P-value
Age (yr) 50.7±11.6 46.1±11.0 0.986
Asymptomatic (n=23) 11 (47.8) 12 (52.2) 0.292
Symptomatic (n=46) 10 (21.7) 36 (78.3) 0.129
Palpability 10 (21.7) 21 (45.7)
Localized pain 0  7 (15.2)
Nipple discharge 0  8 (17.4)
Values are presented as mean±SD or number (%).
DCIS, ductal carcinoma in situ.
Table 2. Comparisons of mammographic findings in the 
underestimated and non-underestimated groups
Variable
Underestimated 
(n=21)
Non- 
underestimated 
(n=48)
P-value
Size on mammography 
(cm)
2.7±0.8 2.1±0.7 0.272
Mammographic finding 0.974
   Negative (n=9) 3 (14.3) 6 (12.5) 0.634
   Positive (n=60) 18 (85.7) 42 (87.5)
      Calcification only 7 (38.9) 19 (45.2)
      Mass 2 (11.1) 3 (7)
      Mass with calcifications 4 (22.2) 9 (21.4)
      Asymmetry 4 (22.2) 7 (16.7)
      Asymmetry with 
      microcalcifications
1 (5.6) 4 (9)
Values are presented as mean±SD or number (%).
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and non-underestimated groups with respect to ultrasonographic 
findings such as shape, orientation, margin, boundary, echogenicity, 
or microcalcification within the mass. 
An axillary lymph node dissection or a sentinel lymph node biopsy 
was performed in all 60 patients. After surgery, none of the 41 
patients in the non-underestimated group had detectable axillary 
lymph node metastases, whereas metastatic axillary lymph nodes 
were present in 3 of 19 patients in the underestimated group 
(P=0.021 by Fisher exact test). Among the seven patients determined 
to have abnormal axillary lymph nodes on ultrasonography, two 
patients in the underestimated group were shown to have lymph 
node metastasis following surgery. One metastatic axillary lymph 
node was actually a lymph node that had been evaluated as benign 
by US. The sensitivity and positive predictive value (PPV) of the 
axillary US findings with the histopathologic correlation of lymph 
node metastasis in the study were 66.7% (2/3) and 28.6% (2/7), 
respectively.
Discussion
Although a US-14G-CNB is a highly accurate and widely used 
method for the diagnosis of breast lesions, sampling errors can 
result in the histologic underestimation of lesions containing atypical 
ductal hyperplasia (ADH) or DCIS, as well as invasive carcinomas. For 
a lesion diagnosed as ADH on needle biopsy and DCIS at surgery, 
underestimation is important because it could lead to a positive 
margin following surgical resection. Lesions diagnosed as DCIS on 
needle biopsy and unsuspected invasive carcinoma at surgery result 
in delayed lymph node biopsies. Thus, patients may have to undergo 
two separate surgical procedures: one procedure for excision of 
the lesion and an additional procedure for axillary lymph node 
evaluation [16]. 
It is useful to identify factors that can predict the DCIS 
underestimation after a US-14G-CNB to make more accurate 
surgical plans and to reduce the potential patient risk and overall 
medical costs. Variable DCIS underestimation rates ranging from 
5%-44% and ADH underestimation rates of 11%-75% have 
been reported, and most biopsies have been performed using 
stereotactic devices with directional vacuum-assisted biopsy in 
addition to automated large-core needle biopsy [5-8,17]. However, 
DCIS underestimation by US-14G-CNB have not previously been 
sufficiently evaluated. In a review of the literature (Table 4), we 
identified the rates of DCIS underestimation in 10 studies following 
US-guided-CNB that ranged from 20% to 66.7%; the original aim 
of these studies was to evaluate the accuracy of a US-guided-CNB 
and not to determine the rate of DCIS underestimation [3,18-26]. 
In the present study, the rate of DCIS underestimation was 30.4% 
(21 of 69 lesions), which is within the range of previously published 
results. That higher rates of DCIS underestimation determined with 
the use of ultrasonography guidance were seen as compared with 
stereotactic biopsy techniques may be due to the fact that most 
US-guided biopsy procedures are performed on a mass, while, the 
most common indication for the use of a stereotactic biopsy is a 
microcalcification. The underestimation of invasive cancer is more 
frequent for a mass than for a microcalcification [17,27]. Some 
Table 3. Comparisons of ultrasonographic findings in the 
underestimated and non-underestimated groups
Variable
Underestimated 
(n=21)
Non-
underestimated 
(n=48)
P-value
Size on ultrasonography 
(cm)
2.3±1.1 1.6±0.8 0.151
Ultrasonographic findings
Shape 0.210
   Oval 4 (19) 19 (39.6)
   Round 2 (9.5) 2 (4.2)
   Irregular 15 (71.4) 27 (56.3)
Orientation 0.276
   Parallel 11 (52.4) 33 (68.8)
   Non-parallel 10 (47.7) 15 (31.3)
Margin 0.103
   Circumscribed 0 2 (4.2)
   Indistinct 4 (19) 16 (33.3)
   Angular 0 0 
   Microlobulated 13 (61.9) 29 (60.4)
   Spiculated 4 (19) 1 (2.1)
Boundary 0.233
   Abrupt 3 (14.3) 14 (29.2)
   Echogenic halo 18 (85.7) 34 (70.8)
Echogenicity 0.365
   Hyperechoic 0 0 
   Isoechoic 3 (14.3) 4 (8.3)
   Hypoechoic 16 (76.2) 41 (85.4)
   Mixed echogenicity 2 (9.5) 3 (6.3)
Microcalcification 
within the mass on 
ultrasonography
11 (52.4) 28 (58.3) 0.793
BI-RADS category 0.148
   4 12 (57.1) 37 (77.1)
   5 9 (42.9) 11 (22.9)
Abnormal lymph 
node in the axilla on 
ultrasonography
5/19 (26.3) 2/41 (4.9) 0.016
Values are presented as mean±SD or number (%).
BI-RADS, Breast Imaging Reporting and Data System. 
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A B
Fig. 1. A 42-year-old woman with a palpable mass in her right 
breast which proved to be an invasive ductal carcinoma. 
A. Mammogram demonstrates suspicious microcalcifications in the 
right breast. B. Breast ultrasonography reveals a 3 cm, irregularly-
shaped and microlobulated margined hypoechoic mass with 
echogenic foci within the right upper outer quadrant. C. Abnormal 
lymph nodes without fatty hilum in the right axilla can be seen. 
The patient underwent an ultrasound-guided 14-gauge core 
needle biopsy with a ductal carcinoma in situ identified based on 
the subsequent histology. Invasive carcinoma was found following 
surgical excision with the presence of metastatic lymph nodes 
detected after axillary lymph node dissection.
C
Fig. 2. A 42-year-old woman with ductal carcinoma in situ. 
A, B. Ultrasonograms demonstrate an irregularly-shaped, hypoechoic mass in the right upper outer portion with a normal appearing lymph 
node (arrows) in the right axilla. The pathologic findings following an ultrasound-guided 14-gauge core needle biopsy and surgical excision 
were consistent with ductal carcinoma in situ.
A B
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ranges. Interestingly, the PPV in this study (28.6%) is lower than in 
previously published reports, which seems to be due to differences 
in the two study populations. While our study was confined to pure 
DCIS with the rare possibility of axillary lymph node metastasis, 
investigators in previous studies evaluated the axillae in patients 
with invasive breast cancers or extensive DCIS (at least 4 cm in 
extent), which are populations that already have a high likelihood of 
axillary lymph node metastases. A comparative analysis determining 
the usefulness of ultrasonographic criteria for predicting axillary 
nodal metastasis in abnormal lymph nodes in different settings with 
a high likelihood of an axillary metastasis or a low risk of lymph 
node metastasis is needed. DCIS is not an invasive malignancy and 
is not able to metastasize to the regional lymph nodes, and less than 
1% to 2% of patients with DCIS who have undergone axillary lymph 
node dissection have been reported to have axillary lymph node 
metastasis [34,35]. In the current study, none of the 41 patients in 
the non-underestimated group who had undergone either axillary 
lymph node dissection or a sentinel lymph node biopsy had lymph 
node metastasis.
A multicenter study that examined factors related to DCIS 
underestimation after a stereotactic biopsy demonstrated that DCIS 
underestimation was more frequent in mass lesions as compared to 
lesions with microcalcifications (24.3% vs. 12.5%, respectively) [17]. 
In addition, they detected DCIS underestimation more frequently 
with the use of automated large-core devices than with the use of 
vacuum-assisted devices (20.4% vs. 11.2%, respectively), with ≤10 
specimens as compared with >10 specimens (17.5% vs. 11.5%, 
respectively) and in lesions >20 mm as compared to lesions <10 mm 
investigators have reported that 90% of carcinomas that present 
as microcalcifications alone were non-infiltrating, whereas 84% of 
carcinomas that present as a mass were invasive [28-30]. These 
investigators concluded that the presence of a mass lesion was a 
significant predictor for the presence of invasion.
It would be useful to identify the preoperative factors involved in 
predicting the presence of occult invasion within DCIS lesions. The 
ability to preoperatively identify patients with a high possibility of 
a co-existing invasive carcinoma might allow sentinel lymph node 
mapping and needle aspiration or a biopsy to be performed prior 
to the initial surgical excision. To identify possible factors involved 
in DCIS underestimation, we compared the underestimated and 
non-underestimated groups and found no statistically significant 
differences between the groups with regard to clinical and imaging 
characteristics, with the exception of the presence of abnormal 
axillary lymph nodes assessed by ultrasonography. Five of 19 
patients (26.3%) in the underestimated group and two of 41 
patients (4.9%) in the non-underestimated group demonstrated 
abnormal lymph nodes by axillary ultrasonography (P=0.016). 
The accuracy of preoperative axillary ultrasonography for nodal 
metastasis in patients with invasive breast cancer has been reported 
in several studies with sensitivities ranging from 35% to 95% and 
PPVs ranging from 69% to 94.9%; these values are dependent 
on the association of specific diagnostic criteria, including lymph 
node shape, length and width, the appearance of the cortex and 
hilum, and the use of color Doppler ultrasonography to define 
suspicious lymph nodes on ultrasonography [31-33]. The sensitivity 
in our current study (66.7%) is within the previously reported 
Table 4. Reported rates of DCIS underestimation after an ultrasound-guided 14-gauge core needle biopsy
Study Target Core needle size (G)
DCIS at CNB/total number 
of biopsied cases (%)
Total number 
underestimated (%)
Smith et al., 2001 [3] Breast mass subtracting 
calcifications only
14 5/128 (1) 1/5 (20)
Schoonjans and Brem, 2001 [24] Breast masses 14 9/424 (2.1) 5/9 (55.5)
Buchberger et al., 2002 [25] Breast masses and calcifications 14 10/590 (1.7) 3/10 (30)
Philpotts et al., 2003 [23] Breast lesions (primarily breast 
masses)
14 2/181 (1.1) 1/2 (50)
Pijnappel et al., 2004 [22] Breast mass and calcifications only 14 or 18 8/128 (6.3) 5/8 (62.5)
Crystal et al., 2005 [21] Breast masses 14 6/715 (0.8) 4/6 (66.7)
Sauer et al., 2005 [20] Breast masses 14 19/962 (2.0) 11/19 (57.9)
Cho et al., 2005 [19] Breast mass (n=551) and 
calcifications (n=11)
14 10/562 (1.8) 5/10 (50)
Youk et al., 2008 [26] Breast masses subtracting 
calcifications only
14 126/2420 (5.2) 36/126 (29)
Schueller et al., 2008 [18] Non-palpable breast masses 14 52/1,061 (4.9) 19/52 (36.5)
Current study Breast mass subtracting 
calcifications only
14 69/3,124 (2.2) 21/69 (30.4)
DCIS, ductal carcinoma in situ; CNB, core needle biopsy; G, gauge.  
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(21.9% vs. 11.9%, respectively) [17]. Histologic factors, including 
high nuclear grade DCIS, comedo subtype, and large size have also 
been reported to significantly increase the likelihood of invasion 
found after surgical resection [27,36]. Recently, Park et al. [37,38] 
reported that underestimation was significantly related to lesion 
palpability, mass or calcification on ultrasonography, and core needle 
biopsy rather than vacuum-assisted biopsy and suggested using 
nomograms for predicting DCIS underestimation. A previous study 
by Lee et al. [9] reported that ultrasonographic lesions >20 mm in 
size were associated with invasive components on final pathology. 
However, in our study, the mean lesion size in the underestimated 
group (2.3 cm) was larger than in the non-underestimated group (1.6 
cm), but this difference was not statistically significant (P=0.151). 
This study had some limitations. First, the sample size of pure 
DCIS after a US-14G-CNB was relatively small. A further study with 
a greater number of cases diagnosed with DCIS after a US-14G-CNB 
is required. Second, the clinicians who performed the biopsies had 
varying levels of experience with the technique, which potentially 
could affect the underestimation rate. Third, the investigators were 
not blind to the biopsy results of the lesions being identified as pure 
DCIS, which could have influenced the retrospective review of the 
images.
In conclusion, the rate of DCIS underestimation in breast masses 
diagnosed as DCIS by a US-14G-CNB in this study was 30.4%. Our 
results underscore the difficulties in predicting possible pathologic 
underestimation solely relying on clinical and imaging findings 
of breast lesions. However, the presence of abnormal axillary 
lymph nodes on ultrasonography may be useful for preoperatively 
predicting DCIS underestimation.
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